Bioventus: Funding, Investors & Team (Aug 2026)
Bioventus is a global leader of active orthopaedic healing, providing clinically proven and cost-effective therapies and diagnostics that help patients regain active lifestyles. Bioventus' products are known for their innovation, safety and effectiveness. The company is the recognized leader in bone stimulation devices and among the leading distributors of osteoarthritis joint fluid therapies. Key products include: - EXOGEN(r) Ultrasound Bone Healing System - SUPARTZ(r) Joint Fluid Therapy (US only) - DUROLANE(r) Hyaluronic Acid, Single Injection (Outside US only) Bioventus' adherence to high quality standards, commitment to evidence-based medicine and strong ethical behavior makes the company a trusted partner for thousands of physicians worldwide. Bioventus employs 500 people and generates about $240 million in yearly revenue. The company is headquartered in Durham, N.C. Prior to launch in 2012, Bioventus was operating as the Biologics Division of Smith & Nephew.
Bioventus has raised $415M across 1 funding round on record, the most recent a Post-IPO Debt of $415M announced in Apr 2022.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Bioventus Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Bioventus Funding Rounds
Bioventus Founders and Leadership Team
Contact details for the Bioventus team: 1 of 1 has an email address on file.
Start 14-day free trial →Bioventus Funding Compared to Other Health Care Startups
Bioventus' latest round of $415M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bioventus in Health Care and Durham
Companies Similar to Bioventus
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
Bioventus Funding FAQs
What does Bioventus do?
Bioventus is a global leader of active orthopaedic healing, providing clinically proven and cost-effective therapies and diagnostics that help patients regain active lifestyles. Bioventus' products are known for their innovation, safety and effectiveness. The company is the recognized leader in bone stimulation devices and among the leading distributors of osteoarthritis joint fluid therapies. Key products include: - EXOGEN(r) Ultrasound Bone Healing System - SUPARTZ(r) Joint Fluid Therapy (US only) - DUROLANE(r) Hyaluronic Acid, Single Injection (Outside US only) Bioventus' adherence to high quality standards, commitment to evidence-based medicine and strong ethical behavior makes the company a trusted partner for thousands of physicians worldwide. Bioventus employs 500 people and generates about $240 million in yearly revenue. The company is headquartered in Durham, N.C. Prior to launch in 2012, Bioventus was operating as the Biologics Division of Smith & Nephew.
How much funding has Bioventus raised?
Bioventus has raised $415M across 1 round on record. The most recent is a Post-IPO Debt of $415M announced in Apr 2022.
When did Bioventus last raise funding?
Bioventus' most recent funding round on record is a Post-IPO Debt of $415M, announced in Apr 2022.
Who is the CEO of Bioventus?
Ken Reali is listed as CEO at Bioventus.
Where is Bioventus headquartered?
Bioventus is based in Durham, North Carolina, United States.
How many employees does Bioventus have?
Bioventus is in the 1001-5000 employee band.
How does Bioventus' funding compare to other Health Care startups?
Bioventus' latest round of $415M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Bioventus Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bioventus is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.